Phospholipid ethers (PLE)

Phospholipid ethers (PLEs) are a class of naturally occurring lipids that are significantly enriched in the plasma membranes of a wide variety of malignant cells compared to normal cells [1.2.1, 1.2.4]. This enrichment is primarily localized within specialized membrane microdomains known as lipid rafts, which are more abundant in cancer cells and play roles in signaling and apoptosis resistance [1.1.2, 1.2.4]. Unlike normal cells, which metabolize and eliminate these lipids, cancer cells exhibit selective uptake and prolonged retention of PLEs [1.2.1, 1.2.5]. This biochemical difference forms the basis for a novel class of therapeutics known as Phospholipid Drug Conjugates (PDCs) [1.1.1, 1.3.3]. Drugs like iopofosine I-131 (CLR 131) exploit this differential distribution by selectively binding to these lipid rafts and entering the cell through a process of trans-membrane inversion [1.1.1, 1.3.1]. Once internalized, the therapeutic payload is delivered directly to the cytosol, where it can exert its effect [1.1.1, 1.3.3]. The metabolic trapping of these molecules in cancer cells ensures high tumor-to-normal tissue ratios, minimizing off-target effects [1.2.5]. This target provides a broad-spectrum approach for treating various solid and hematologic tumors, including multiple myeloma and Waldenström macroglobulinemia [1.1.4, 1.3.2].

Other names

AlkylphosphocholinesAPCsEther lipidsTumor-selective phospholipid ethersLipid rafts (target domain)

Selective binding to lipid rafts in malignant cell membranes followed by trans-membrane inversion (flip-flop) and metabolic trapping within the tumor cell [1.1.1, 1.2.5].